|Bid||40.94 x 1400|
|Ask||0.00 x 800|
|Day's Range||46.70 - 46.70|
|52 Week Range||11.27 - 47.08|
|Beta (3Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.22|
NEW YORK / ACCESSWIRE / October 17, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
WILMINGTON, Del., Oct. 17, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Ra Pharmaceuticals, Inc. (NASDAQ GS: RARX) regarding possible breaches of.
BALA CYNWYD, PA / ACCESSWIRE / October 16, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Ra Pharmaceuticals, Inc. ("Ra ...
NEW YORK, Oct. 16, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
NEW YORK, Oct. 15, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Ra Pharmaceuticals, Inc. (NASDAQ: RARX)The.
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-rarx/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
NEW YORK , Oct. 11, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Roku (NASDAQ: ROKU ) shares were up 5.5% to ...
Ra Pharma stock rocketed by more than 100% Thursday after Belgium biotech company UCB agreed to acquire it for $2.1 billion. Ra Pharma is working on a treatment for a muscular condition.
NEW YORK, Oct. 10, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Ra Pharmaceuticals, Inc. (“Ra.
The Cambridge biotech, which is in late-stage trials of a drug to treat a rare muscle disease, has been acquired by Belgium-based UCB for $2.1 billion, immediately doubling the market value of the Cambridge firm.
NEW YORK , Oct. 10, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on behalf of Ra Pharma shareholders ...
NEW YORK , Oct. 10, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Ra Pharmaceuticals, Inc. ("RARX" or the ...
WILMINGTON, DE / ACCESSWIRE / October 10, 2019 / Rigrodsky & Long, P.A.: Do you own shares of Ra Pharmaceuticals, Inc. (NASDAQ GS: RARX )? Did you purchase any of your shares prior to October 10, 2019? ...
NEW YORK, Oct. 10, 2019 -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) to UCB S.A. (“UCB”).
Ra Pharm is a clinical-stage biopharma engaged in the development of therapies for serious diseases caused by excessive activation of the complement system, a critical component of the innate immune system. UCB is paying $48 per share in cash for the company, or $2.5 billion. Net of Ra Pharma's cash, the transaction is valued at $2.1 billion.
SAN DIEGO , Oct. 10, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) ("Ra ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...
Belgian biopharma company UCB has agreed to acquire Ra Pharmaceuticals Inc. in a cash deal valued at about $2.5 billion, the companies said Thursday. Ra Pharma shareholders will receive $48 per share, equal to a 93% premium over the 30-day volume weighted closing stock price of Ra Pharma prior to signing. The deal has been approved by the boards of both companies and is expected to close by the end of the first quarter of 2020. Cambridge, Mass-based Ra Pharma is a clinical-stage biopharma company focused on development treatments for serious diseases caused by the immune system. "The company's ExtremeDiversity(TM) platform enables the production of synthetic macrocyclic peptides combining the diversity and specificity of antibodies with the pharmacological properties of small molecules," said the statement. The company's phase 3 product candidate zilucoplan had positive results in a phase 2 trial as a treatment for myasthenia gravis, of gMG, a chronic auto-immune condition in which auto-antibodies attack specific proteins in the neuro-muscular junction. That causes muscle weakness and fatigue and affects almost 200,000 patients in the U.S., EU and Japan, said the statement. Ra Pharma shares rose 107% in premarket trade on the news, and are up 25% in 2019 through Wednesday, while the S&P 500 has gained 16%.
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, ...
Shares of biotech company Ra Pharmaceuticals more than double after Belgian-based biotech firm UCB announces it is acquiring the company for $2.1 billion in cash.
UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, both companies reported on Thursday, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology. "Ra Pharma is an excellent strategic fit addressing multiple areas of UCB's patient value growth strategy," UCB's Chief Executive Officer Jean-Christophe Tellier said in a joint statement. The acquisition of the clinical-stage biopharmaceutical company, which was founded in 2008, is expected to contribute to UCB's core earning per share and increase its revenue and net profit from 2024 onwards.